Full TitleA Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
The purpose of this study is to find the best dose of the investigational drug DCC-3014 that can be used safely in patients with diffuse-type tenosynovial giant cell tumor (DTGCT), a benign disease that can develop in the joints and cause significant damage. DCC-3014 helps fight cancer by inhibiting a protein called CSF1. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have DTGCT that is inoperable or causing symptoms.
- At least 2 weeks must pass between the completion of any prior therapy and receipt of DCC-3014.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. William Tap at 646-888-4163.